
Danish Zealand Pharma recently announced that the company has signed a collaboration deal with the privately owned US biotech company Protagonist Therapeutics.
According to the terms of the contract Zealand Pharma and Protagonist will join forces in identifying, optimizing and developing new peptides with the potential to offer better treatments for patients within defined, un-disclosed disease areas.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app